Clinical Trial: Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional




Official Title: Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy

Brief Summary: Blood circulating endothelial cells (CEC) and microparticles (MPs) are described in the literature to be associated with vascular failures and dysfunction that reflect neo-angiogenesis and risk of thrombosis, respectively. There a few number of CEC in healthy patients although they significantly increase in several cancers including myeloma. However, no study explored to date a correlation of CEC and/or circulating endothelial progenitors (CEP) and MPs with the tumoral growth of monoclonal gammopathy. On the other hand, there is no study measuring the CEC and CEP directly in the bone marrow. The investigators aim is to evaluate these 2 original features in patients with monoclonal gammopathy: monoclonal gammopathy of undetermined signification (MGUS) and myeloma. This is a preliminary multicentric study.